Neuroimaging in amyotrophic lateral sclerosis

References

• Poloni M, Mascherpa C, Faggi L et al. Cerebral atrophy in motor neuron disease evaluated by computed tomography. J Neurol Neurosurg Psychiatry 1982; 45(12): 1102–1105.
   Google Scholar
• Kato S, Hayashi H, Yagishita A. Involvement of the frontotem- poral lobe and limbic system in amyotrophic lateral sclerosis: as assessed by serial computed tomography and magnetic resonance imaging. J Neurol Sci 1993; 116(1): 52–58.
   PubMed Web of Science ®Google Scholar
• Peretti-Viton P, Azulay JP, Trefouret S et al. MRI of the intracranial corticospinal tracts in amyotrophic and primary lateral sclerosis. Neuroradiology 1999; 41(10): 744–749.
   Google Scholar
• Sarchielli P, Pelliccioli GP, Tarducci R et al. Magnetic resonance imaging and 1H-magnetic resonance spectroscopy in amyo- trophic lateral sclerosis. Neuroradiology 2001; 43(3): 189–197.
   Google Scholar
• Yamauchi H, Fukuyama H, Ouchi Y et al. Corpus callosum atrophy in amyotrophic lateral sclerosis. J Neurol Sci 1995; 134(1–2): 189–196.
   Google Scholar
• Gallassi R, Montagna P, Morreale A et al. Neuropsychological, electroencephalogram and brain computed tomography findings in motor neuron disease. Eur Neurol 1989; 29(2): 115–120.
   Google Scholar
• Andreadou E, Sgouropoulos P, Varelas P et al. Subcortical frontal lesions on MRI in patients with motor neuron disease. Neuroradiology 1998; 40(5): 298–302.
   Google Scholar
• Ellis CM, Suckling J, Amaro JE Jr et al. Volumetric analysis reveals corticospinal tract degeneration and extramotor involvement in ALS. Neurology 2001; 57(9): 1571–1578.
   Google Scholar
• Frank B, Haas J, Heinze HJ et al. Relation of neuropsychological and magnetic resonance findings in amyotrophic lateral sclerosis: evidence for subgroups. Clin Neurol Neurosurg 1997; 99(2): 79–86.
   Google Scholar
• Abe K, Fujimura H, Toyooka K et al. Cognitive function in amyotrophic lateral sclerosis. J Neurol Sci 1997; 148(1): 95–100.
   Google Scholar
• Abe K, Fujimura H, Kobayashi Y et al. Degeneration of the pyramidal tracts in patients with amyotrophic lateral sclerosis. A premortem and postmortem magnetic resonance imaging study. Journal of Neuroimaging 1997; 7(4): 208–212.
   Google Scholar
• Hecht MJ, Fellner F, Fellner C et al. MRI-FLAIR images of the head show corticospinal tract alterations in ALS patients more frequently than T2-, T1- and proton-density-weighted images. J Neurol Sci 2001; 186(1–2): 37–44.
   Google Scholar
• Waragai M. MRI and clinical features in amyotrophic lateral sclerosis. Neuroradiology 1997; 39(12): 847–851.
   Google Scholar
• Yagishita A, Nakano I, Oda M, Hirano A. Location of the corticospinal tract in the internal capsule at MR imaging. Radiology 1994; 191(2): 455–460.
   Google Scholar
• Oba H, Araki T, Ohtomo K et al. Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology 1993; 189(3): 843–846.
   Google Scholar
• Iwasaki Y, Ikeda K, Shiojima T et al. Clinical significance of hypointensity in the motor cortex on T2- weighted images. Neurology 1994; 44(6):1181.
   Google Scholar
• Udaka F, Sawada H, Seriu N et al. and SPECT findings in amyotrophic lateral sclerosis. Demonstration of upper motor neuron involvement by clinical neuroimaging. Neuroradiology 1992; 34(5): 389–393.
   Google Scholar
• Abe K, Fujimura H, Toyooka K et al. Single-photon emission computed tomographic investigation of patients with motor neuron disease. Neurology 1993; 43(8): 1569–1573.
   Google Scholar
• Dalakas MC, Hatazawa J, Brooks R et al. Lowered cerebral glucose utilization in amyotrophic lateral sclerosis. Ann Neurol 1987; 22(5): 580–586.
   Google Scholar
• Kew JJ, Leigh PN, Playford ED et al. Cortical function in amyotrophic lateral sclerosis. A positron emission tomography study. Brain 1993; 116(Pt 3): 655–680.
   Google Scholar
• Lloyd CM, Richardson MP, Brooks DJ et al. Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil. Brain 2000; 123(Pt 11): 2289–2296.
   Google Scholar
• Kew JJ, Brooks DJ, Passingham RE et al. Cortical function in progressive lower motor neuron disorders and amyotrophic lateral sclerosis: a comparative PET study. Neurology 1994; 44(6): 1101–1110.
   Google Scholar
• Brooks BR, Bushara K, Khan A et al. Functional magnetic resonance imaging (fMRI) clinical studies in ALS: paradigms, problems and promises. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1 Suppl 2: S23–S32.
   Google Scholar
• Konrad C, Henningsen H, Bremer J et al. Pattern of cortical reorganization in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study. Exp Brain Res 2002; 143(1): 51–56.
   Google Scholar
• Kew JJ, Goldstein LH, Leigh PN et al. The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis. A neuropsychological and positron emission tomography study. Brain 1993; 116(Pt 6): 1399–1423.
   Google Scholar
• Abrahams S, Goldstein LH, Kew J et al. Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study. Brain 1996; 119(Pt 6): 2105–2120.
   Google Scholar
• Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991; 45(1): 37–45.
   PubMed Web of Science ®Google Scholar
• Moffett JR, Namboodiri MA, Cangro CB, Neale JH. Immuno- histochemical localization of N-acetylaspartate in rat brain. Neuroreport 1991; 2(3): 131–134.
   PubMedGoogle Scholar
• Pioro EP, Antel JP, Cashman NR, Arnold DL. Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology 1994; 44(10): 1933–1938.
   PubMed Web of Science ®Google Scholar
• Parent A. Carpenter’s Human Neuroanatomy. 9 ed. Baltimore: Williams and Wilkins, 1996.
   Google Scholar
• Martin JE, Swash M. The pathology of motor neuron disease. In: Leigh PN, Swash M, (eds.) Motor Neuron Disease. Biology and Management. London: Springer-Verlag, 1995: 93–118.
   Google Scholar
• Jones AP, Gunawardena WJ, Coutinho CM et al. Preliminary results of proton magnetic resonance spectroscopy in motor neuron disease (amyotrophic lateral sclerosis). J Neurol Sci 1995; 129 Suppl: 85–89.
   Google Scholar
• Giroud M, Walker P, Bernard D et al. Reduced brain N- acetyl-aspartate in frontal lobes suggests neuronal loss in patients with amyotrophic lateral sclerosis. Neurological Research 1996; 18(3): 241–243.
   Google Scholar
• Gredal O, Rosenbaum S, Topp S et al. Quantification of brain metabolites in amyotrophic lateral sclerosis by localized proton magnetic resonance spectroscopy. Neurology 1997; 48(4): 878–881.
   Google Scholar
• Rooney WD, Miller RG, Gelinas D et al. Decreased N-acetylaspartate in motor cortex and corticospinal tract in ALS. Neurology 1998; 50(6): 1800–1805.
   Google Scholar
• Block W, Karitzky J, Traber F et al. Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements. Arch Neurol 1998; 55(7): 931–936.
   Google Scholar
• Strong MJ, Grace GM, Orange JB et al. prospective study of cognitive impairment in ALS. Neurology 1999; 53(8): 1665–1670.
   Google Scholar
• Chan S, Shungu DC, Douglas-Akinwande A et al. Motor neuron diseases: comparison of single-voxel proton MR spectroscopy of the motor cortex with MR imaging of the brain. Radiology 1999; 212(3): 763–769.
   Google Scholar
• Bowen BC, Pattany PM, Bradley WG et al. imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol 2000; 21(4): 647–658.
   Google Scholar
• Pohl C, Block W, Karitzky J et al. Proton magnetic resonance spectroscopy of the motor cortex in 70 patients with amyo- trophic lateral sclerosis. Arch Neurol 2001; 58(5): 729–735.
   Google Scholar
• Vielhaber S, Kaufmann J, Kanowski M et al. Effect of creatine supplementation on metabolite levels in ALS motor cortices. Exp Neurol 2001; 172(2): 377–382.
   Google Scholar
• Schuff N, R.ooney WD, Miller R et al. Reanalysis of multislice (1)H MRSI in amyotrophic lateral sclerosis. Magn Reson Med 2001; 45(3): 513–516.
   Google Scholar
• Abe K, Takanashi M, Watanabe Y et al. Decrease in N-acetylaspartate/creatine ratio in the motor area and the frontal lobe in amyotrophic lateral sclerosis. Neuroradiology 2001; 43(7): 537–541.
   Google Scholar
• Kenn W, Ochs G, Pabst TA, Hahn D. 1H spectroscopy in patients with amyotrophic lateral sclerosis. J Neuroimaging 2001; 11(3): 293–297.
   PubMed Web of Science ®Google Scholar
• Suhy J, Miller RG, Rule R et al. Early detection and longitudinal changes in amyotrophic lateral sclerosis by 1H MRSI. Neurology 2002; 58: 773–779.
   Google Scholar
• Hanstock CC, Cwik VA, Martin WR. Reduction in metabolite transverse relation times in amyotrophic lateral sclerosis. J Neurol Sci 2002; 198: 37–41.
   PubMed Web of Science ®Google Scholar
• Kalra S, Genge A, Arnold DL. A prospective, randomized, placebo-controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results. ALS and Other Motor Neuron Disorders 2003; 4(1): 22–26.
   PubMed Web of Science ®Google Scholar
• Kalra S, Cashman NR, Caramanos Z et al. Magnetic resonance spectroscopic imaging reveals lack of improvement in neuronal integrity with gabapentin therapy. American Journal of Neuro- radiology 2003; 24(3): 476–480.
   Google Scholar
• Kalra S, Cashman NR, Genge A, Arnold DL. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 1998; 9(8): 1757–1761.
   PubMed Web of Science ®Google Scholar
• Cwik VA, Hanstock CC, Allen PS, Martin WR. Estimation of brainstem neuronal loss in amyotrophic lateral sclerosis with in vivo proton magnetic resonance spectroscopy. Neurology 1998; 50(1): 72–77.
   PubMed Web of Science ®Google Scholar
• Pioro EP, Majors AW, Mitsumoto H et al. 1H-MRS evidence of neurodegeneration and excess glutamatezglutamine in ALS medulla. Neurology 1999; 53(1): 71–79.
   Google Scholar
• Matthews PM, Cianfaglia L, McLaurin J et al. Demonstration of reversible decreases in N-acetylaspartate (NAA) in a neuronal cell line: NAA decreases as a marker of sublethal neuronal dysfunction. Proceedings of the Society of Magnetic Resonance and the European Society for Magnetic Resonance in Medicine and Biology 1, 147. 1995. (Abstract)
   Google Scholar
• Dautry C, Vaufrey F, Brouillet E et al. Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3- nitropro- pionic acid. J Cereb Blood Flow Metab 2000; 20(5): 789–799.
   Google Scholar
• Gasparovic C, Arfai N, Smid N, Feeney DM. Decrease and recovery of N-acetylaspartate/creatine in rat brain remote from focal injury. J Neurotrauma 2001; 18(3): 241–246.
   PubMed Web of Science ®Google Scholar
• Demougeot C, Garnier P, Mossiat C et al. N-Acetylaspartate, a marker of both cellular dysfunction and neuronal loss: its relevance to studies of acute brain injury. J Neurochem 2001; 77(2): 408–415.
   Google Scholar
• De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. MRM 1995; 34(5): 721–727.
   PubMed Web of Science ®Google Scholar
• Uno M, Ueda S, H.ondo H et al. Effectiveness of revasculariza- tion surgery evaluated by proton magnetic resonance spectro- scopy and single photon emission computed tomography. Neurologia Medico-Chirurgica 1996; 36(8): 560–566.
   Google Scholar
• Cendes F, Andermann F, Dubeau F et al. Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy. Evidence from proton MR spectroscopic imaging. Neurology 1997; 49(6): 1525–1533.
   Google Scholar
• Vion-Dury J, Nicoli F, Salvan AM et al. Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonance spectroscopy. Lancet 1995; 345(8941): 60–61.
   Google Scholar
• Moore GJ, Bebchuk JM, Hasanat K et al. Lithium increases N- acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2’s neurotrophic effects? Biological Psychiatry 2000; 48(1): 1–8.
   Google Scholar
• Kalra S, Arnold DL, Cashman NR. Biological markers in the diag- nosis and treatment of ALS. J Neurol Sci 1999; 165 (Suppl 1): S27–S32.
   Google Scholar
• Andreassen OA, Jenkins BG, Dedeoglu A et al. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J Neurochem 2001; 77(2): 383–390.
   Google Scholar
• Ellis CM, Simmons A, Jones DK et al. Diffusion tensor MRI assesses corticospinal tract damage in ALS. Neurology 1999; 53(5): 1051–1058.
   Google Scholar
• Kato Y, Matsumura K, Kinosada Y et al. Detection of pyramidal tract lesions in amyotrophic lateral sclerosis with magnetization- transfer measurements. Ajnr: American Journal of Neuroradiol- ogy 1997; 18(8): 1541–1547.
   Google Scholar
• Tanabe JL, Vermathen M, Miller R et al. Reduced MTR in the corticospinal tract and normal T2 in amyotrophic lateral sclerosis. Magnetic Resonance Imaging 1998; 16 (10):1163– 1169.
   Google Scholar